AEHR Diversification Narrative Expands, Yet Shipment Proof Remains Elusive

What happened

Aehr Test Systems is actively broadening its story beyond silicon carbide (SiC) testing, highlighting early traction in AI burn-in systems (Sonoma) for hyperscalers, silicon photonics qualifications, and a recovering power semiconductor segment. The latest Zacks commentary frames this diversification as a potential growth accelerator, but the company’s reported financials continue to show lumpy revenue, a 44% year-over-year revenue decline to $10.3 million in the most recent quarter, and a net loss of $(3.2) million. Backlog and bookings are strong, with a record $41 million production order from a lead hyperscaler and over $92 million in second-half FY26 bookings, yet purchase orders are cancellable and customer concentration remains extreme (42% of quarterly revenue from one customer). The upgraded contract manufacturing capacity and expectations to begin shipping Sonoma systems 'this quarter' are positive operational signals, but they have not yet translated into sustained shipment-driven revenue growth or improved margins. Overall, the diversification theme is real but unproven, and the stock at $115 already prices a steep ramp that hinges on converting orders into on-time, profitable shipments.

Implication

Investors should demand concrete evidence that diversification reduces single-customer dependence: watch for multiple repeat orders in silicon photonics and AI burn-in, and for quarterly revenue to exceed $20–$25 million with gross margin improvement. Until then, the risk/reward remains unattractive at $115, as dilution risk (recently completed $60M ATM) and order pushouts could pressure the stock toward the $85 bear scenario. A breakout above $130 is only justified if the next two quarters show shipment-driven growth from more than one large customer.

Thesis delta

This news does not materially change the thesis; it simply reiterates the diversification narrative already present in the master report. The core issue remains whether Aehr can convert record bookings into sequential revenue growth and margin recovery without further dilution, while reducing extreme customer concentration. We maintain the WAIT rating and $115 base value until shipment and gross margin proof emerges.